A CME-certified/ABIM MOC-eligible Activity
Click here to complete your registration.
If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.
DATES AND TIMES
- Welcome and Introductions
- Renal and Cardiovascular Disease: Role of the Mineralocorticoid Receptor
- Mineralocorticoid Receptor Antagonists: Efficacy, Safety, and in Practice
- Questions and Answers
T2DM is the leading cause of CKD worldwide and CVD is the leading cause of morbidity and mortality for patients with T2DM and for patients with CKD. People with T2DM and CKD are at increased risk for CVD and CV death compared with those with T2DM alone. Even with optimal medical therapy, these patients remain at high risk for CVD events and progression to ESRD. MRAs are recommended for the treatment of resistant HTN and for managing HF in patients with T2DM and CKD. Lack of guidelines for the use of MRAs and fear of hyperkalemia has resulted in many eeligible patients not being given MRAs, receiving them late in disease course, and/or are not receiving optimal dosing. New nonsteroidal MRAs are associated with a lower incidence of hyperkalemia and improved CKD and CVD benefits.
Mineralocorticoid Receptor Antagonists: Addressing Residual Risk in Patients with Cardiac Disease, T2DM, and CKD will provide cardiologists with information about the interrelationship of CVD and renal disease and the efficacy and safety of MRAs as well as expert guidance about the role of MRAs in the management of patients with T2DM, CKD, and CVD.
Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC
Associate Professor of Medicine and Epidemiology
Associate Director of Preventive Cardiology
Ciccarone Center for the Prevention of Heart Disease
Division of Cardiology, Johns Hopkins School of Medicine
Muthiah Vaduganathan, MD, MPH
Co-Director, Center for Cardiometabolic Implementation Science
Brigham and Women’s Hospital
Harvard Medical School
This activity is intended for cardiologists, who are clinicians responsible for the evaluation and management of patients with diabetes, chronic kidney disease, and heart disease.
At the conclusion of this activity, participants should be able to:
- Discuss the role of the mineralocorticoid receptor in the development and progression of renal and cardiovascular disease.
- Evaluate for and monitor CKD in patients with T2DM and cardiac disease.
- Assess the data for the efficacy and safety of approved mineralocorticoid receptor antagonists.
- Incorporate mineralocorticoid receptor antagonists into management plans for patients with CKD, T2DM, and cardiovascular disease.
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATION STATEMENT
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit or the evaluation, please email firstname.lastname@example.org.
ABIM MOC RECOGNITION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
ABMS MOC APPROVAL STATEMENT
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory,Mineralocorticoid Receptor Agonists: Addressing Residual Risk in Patients with Cardiac Disease, T2DM, and CKD has met the requirements as a Lifelong Learning CME Activity(apply toward general CME requirement) for the following ABMS Member Boards:
ABMS Lifelong Learning CME Activity
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by PCME. The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.
Disclosure and mitigation information will be made known to the participants prior to the start of the activity.
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
To ensure your computer is compatible for the live event, please perform a system check by clicking on the link http://livewebcast.net/test or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer is compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.
1.4 GHz Intel Pentium 4 or faster processor (or equivalent) Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit) 512 MB of RAM (1 GB recommended) Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome For HTML Client - Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above) 1.83 GHz Intel Core Duo or faster processor 512 MB RAM (1 GB recommended) Mac OS X 10.12, 10.13 and 10.14 Mozilla Firefox, Apple Safari, Google Chrome For HTML Client - Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above) The Adobe Connect app for iOS and Android requires Adobe Connect Server version 8.2 or later Some features may not be enabled in all Adobe Connect meetings if one is using an Adobe Connect Server older than version 9.4.2 (required for Custom pods) Google Android 4.4 or later Apple iOS: iOS 8.1.2 or later
DSL/cable (wired connection recommended)
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT AND MOC POINTS
There is no fee for this activity. To receive credit, participants must register, view the live CME/MOC activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is one hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.
Jointly provided by the Potomac Center for Medical Education and Rockpointe
program is supported by an educational grant from Bayer HealthCare Pharmaceuticals